FRX News 99.77 06/30/2014 04:55:39 Forest Laboratories (FRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Forest Laboratories (FRX) 99.77 $FRX

Global Hypertension Drugs Market 2014-2018
M2 - Thu Jun 26, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tw2n66/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. The Global Hypertension Drugs market will grow at a CAGR of 1.2% to 2018 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary. The Global Hypertension Drugs market can be categorized into eight segments: - Diuretics - ACE Inhibitors - ARBs - CCB - Beta Blockers - Alpha Blockers - Vasodilators - Renin Inhibitors To calculate the market size, the report considers the revenue generated from the sales of various hypertension drugs used in the treatment of pulmonary arterial hypertension and essential hypertension. The report, the Global Hypertension Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Hypertension Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Novartis AG - Pfizer Inc. - Sanofi SA Other Prominent Vendors - Bayer AG - Daiichi Sankyo Co. Ltd. - Forest Laboratories Inc. - Merck & Co. Inc. - Takeda Pharmaceutical Co. Ltd. - United Therapeutics Corp. - Valeant Pharmaceuticals International Inc. - XOMA LLC Key Market Drivers/Challenges/Trends - Increase in Aging Population. - Increasing Number of Patent Expirations. - Increasing Focus on Combination Therapies. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Late Stage Pipeline Snapshot - Market Segmentation by Mechanism of Action - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/tw2n66/global

Leadership Appointments, Approved Acquisitions, Licensing Agreements, Technical UPdate, and Response to Tender Offer Announcement - Analyst Notes on Actavis, Forest, Vertex, MannKind and Gentiva
PR Newswire - Thu Jun 26, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Forest Laboratories Inc. (NYSE: FRX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), MannKind Corp. (NASDAQ: MNKD) and Gentiva Health Services Inc. (NASDAQ: GTIV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4129-100free.

Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire - Tue Jun 24, 5:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:

Forest Laboratories Reports Positive Data on Viibryd - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 5:20PM CDT
Forest Laboratories, Inc. (FRX) announced positive top-line results from three phase III trials evaluating the efficacy, safety and tolerability of Viibryd in adults suffering from generalized anxiety disorder.

Forest Laboratories (FRX) Breaks Through Resistance at $99.51
Comtex SmarTrend(R) - Tue Jun 24, 10:12AM CDT
Forest Laboratories (NYSE:FRX) has opened bullishly above the pivot of $98.69 today and has reached the first level of resistance at $99.51. Investors may be interested in a cross of the next upside pivot targets of $100.28 and $101.87.

Actavis and Forest Announce Tentative Election Deadline of June 27, 2014
Business Wire - Tue Jun 24, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis' planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27, 2014 (the "Election Deadline" . The Election Deadline may be extended, in which case Actavis and Forest will issue a press release announcing the new election deadline. Subject to regulatory approval and other customary closing conditions, the closing date of the acquisition is expected to be July 1, 2014. Forest stockholders who hold shares through a bank, broker, trust company or other nominee may have an earlier election deadline and should carefully review any instructions received from their bank, broker, trust company or other nominee.

Forest Laboratories, Inc. Announces Positive Topline Results from Three Phase III Trials for Vilazodone in the Treatment of Generalized Anxiety Disorder (GAD)
Business Wire - Mon Jun 23, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD). In two flexible-dose and one fixed-dose GAD trials, patients who received vilazodone demonstrated statistically significant improvement from baseline in the Hamilton Rating Scale for Anxiety (HAM-A) total score versus placebo at week 8, the primary endpoint.

3 Stocks Driving The Health Care Sector Higher
at The Street - Mon Jun 23, 12:09PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

Trade-Ideas: Forest Laboratories (FRX) Is Today's Momo Momentum Stock
at The Street - Mon Jun 23, 9:01AM CDT
Trade-Ideas LLC identified Forest Laboratories (FRX) as a momo momentum candidate

Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
Business Wire - Mon Jun 23, 7:30AM CDT
--- Proven Development Track Record in Key Therapeutic Categories including Women's Health, Psychiatric and Cardiovascular -

Forest Laboratories, Inc. to Present Cariprazine Data at the International College of Neuropsychopharmacology World Congress
Business Wire - Fri Jun 20, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that data on the investigational drug cariprazine will be presented at the International College of Neuropsychopharmacology (CINP) 29th World Congress, scheduled June 22-26, 2014 in Vancouver, Canada.

Research and Markets: Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
Business Wire - Fri Jun 20, 10:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vvmps/cariprazine) has announced the addition of the "Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - Fri Jun 20, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d7b94m/cariprazine) has announced the addition of the "Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. Cariprazine (RGH-188) is being developed as an adjunctive treatment to antidepressant therapy in patients with MDD who had an inadequate response to antidepressant therapy, and as of April 2014, two Phase III clinical trials were ongoing (Forest Laboratories, NCT01715805; Forest Laboratories, NCT01838876). In addition, cariprazine is being developed for the treatment of schizophrenia and bipolar disorder. Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Cariprazine including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Cariprazine for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Classification - Symptoms and Subtypes of Major Depressive Disorder - Prognosis - Quality of Life 4 Disease Management - Diagnosis - Treatment Guidelines and Leading Prescribed Drugs - Clinical Practice 5 Competitive Assessment 6 Unmet Needs and Opportunities - More Effective Pharmacotherapies - More Favorable Side Effect Profiles - Rapid Onset of Antidepressant Effects - Personalized Treatment Approach 7 Pipeline Assessment 8 Cariprazine (RGH-188) 9 Appendix For more information visit http://www.researchandmarkets.com/research/d7...ariprazine

Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.

Will Forest Laboratories (FRX) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 7:50AM CDT
Recent estimates have been moving higher for Forest Laboratories.

Forest Laboratories acquires extended US market pediatric exclusivity for NAMENDA and NAMENDA XR by six months
M2 - Thu Jun 19, 4:56AM CDT
Pharmaceutical company Forest Laboratories (NYSE:FRX) said on Wednesday that it has received the US Food and Drug Administration's (FDA) pediatric exclusivity for memantine hydrochloride.

Nasdaq, S&P 500 Rally To New Highs After Fed Meeting
at Investor's Business Daily - Wed Jun 18, 3:20PM CDT
The major averages rallied after the Fed said it would keep interest rates near zero and trimmed monthly bond purchases by $10 billion, to $35 billion. The Fed lowered its 2014 economic growth forecast to between 2.1% and 2.3%, from 2.9%, but said...

Next Resistance Level for Forest Laboratories (FRX) is $99.30
Comtex SmarTrend(R) - Wed Jun 18, 9:02AM CDT
Shares of Forest Laboratories (NYSE:FRX) have bullishly opened above the pivot of $96.19 today and have reached the first resistance level of $97.94. Analysts will be watching for a cross of the next upside pivot targets of $99.30 and $102.41.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 31

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 61

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 48

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 35

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 44

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 51

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 71

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 55

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
Older Adults Embrace Cosmetic Dentistry for Confidence

Updated Category News Views 139

Why the Shift to Cosmetic Dentistry Later in Life? Aging doesn't just wrinkle your skin; it affects your smile too. Dr. Joseph T. Sumrall and Dr. Gran Sumrall, the dental gurus of Warner Robins, Georgia, are laying out why more adults are jumping on the cosmetic dentistry bandwagon as they age. Spoiler: It ain't about getting a movie-star grin but something much deeper....

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading

Top 5 Most Recently Viewed Articles

Cytek Biosciences Prepares for Q2 2025 Financial Results Report

Updated Category News Views 214

Cytek Biosciences Plans Financial Disclosure for Second Quarter 2025 Cytek Biosciences, Inc. (NASDAQ: CTKB), based in Fremont, California, has dynamic news for stakeholders. The company is set to disclose its financial results for the second quarter of 2025 on August 6, 2025. This critical deadline follows the market closure that day, allowing for a comprehensive analysis...

Continue Reading
Alliance Trust PLC Shares Up: Latest NAV Per Share Insights

Updated Category News Views 171

Alliance Trust PLC Alliance Trust PLC's recent trading data dropped some key numbers that had traders buzzing. The Net Asset Value (NAV) per ordinary share hit the screens, giving everyone a fresh angle on how the company was really performing in a choppy market. NAV Breakdown: What's It Telling Us? Here's how the NAV shook out on the latest report: Valued on a Bid Price...

Continue Reading
Man Group Investment Insights: Spirent Communications and Trends

Updated Category News Views 199

Investment Insights from Man Group regarding Spirent Communications In today’s evolving market, understanding the dynamics between significant firms like Man Group PLC and Spirent Communications plc is vital for investors. This disclosure provides a snapshot of Man Group’s holdings and interests, particularly in relation to investing more than 1% in relevant...

Continue Reading
Sunny Lowe Joins Prime Mining Corp's Board of Directors

Updated Category News Views 221

Prime Mining Corp. (TSX: PRYM) (Other OTC: PRMNF) (Frankfurt: O4V3) has recently appointed Sunny Lowe to its Board of Directors. This announcement highlights a strategic move by the company to strengthen its leadership team as it continues its key projects, particularly the Los Reyes Project. Welcome to Sunny Lowe Murray John, Chair of the Board, expressed enthusiasm...

Continue Reading
Spotlight on Magnificent 7 Stocks: Opportunities in a Turbulent Market

Updated Category News Views 190

Market Overview: Understanding the Current Landscape The technology sector has seen major fluctuations recently, prompting discussions about the best investment opportunities. Economic uncertainties and market instability have resulted in significant stock losses, making this a pivotal moment for investors. The backdrop of Trump’s trade policies adds another layer of...

Continue Reading